Ribonucleotide reductase as a therapeutic target for drug repurposing as anthelmintics

被引:2
|
作者
Panesso, Marcelo Pasa [1 ,2 ,3 ]
Cancela, Martin
Cora, Renato Kulakowski [1 ,2 ,3 ]
Paes, Jessica Andrade [1 ,2 ,3 ]
Paludo, Gabriela Prado [1 ,2 ,3 ]
Ferreira, Henrique Bunselmeyer [1 ,2 ,4 ]
机构
[1] Univ Fed Rio Grande do Sul UFRGS, Ctr Biotecnol, Lab Genom Estrutural & Func, Porto Alegre, Brazil
[2] Ctr Biotecnol, Lab Biol Mol Cestodeos, UFRGS, Porto Alegre, Brazil
[3] Univ Fed Rio Grande do Sul, Ctr Biotecnol, Programa Posgrad Biol Celular & Mol, Porto Alegre, Brazil
[4] Univ Fed Rio Grande do Sul, Inst Biociencias, Dept Biol Mol & Biotecnol, Porto Alegre, Brazil
关键词
Nucleotide synthesis; Echinococcus granulosus; Helminthiasis; Druggability; Drug repurposing; IN-VITRO; ECHINOCOCCUS; HYDROXYUREA; METABOLISM;
D O I
10.1016/j.exppara.2023.108641
中图分类号
R38 [医学寄生虫学]; Q [生物科学];
学科分类号
07 ; 0710 ; 09 ; 100103 ;
摘要
Visceral cestodiases, like echinococcoses and cysticercoses, are zoonoses of worldwide distribution and are responsible for public health problems in many countries, especially in underdeveloped regions. Current treatments have low efficiency and there are few drugs currently in use for chemotherapy, making the development of new anthelmintics an urgent matter. The nucleotide salvage pathways are the only ones available for nucleotide synthesis in cestodes and other parasitic helminths, and, here, we used in silico approaches to assess the potential of the enzymes in these pathways as targets for drug repurposing as anthelminthics. First, a genomic survey allowed to identify a repertoire of 28 enzymes of the purine and pyrimidine salvage pathways from the cestode Echinococcus granulosus sensu stricto. Regarding purines, the parasite relies on salvaging free bases rather than salvaging nucleosides. Pyrimidines, on the other hand, can be salvaged from both bases and nucleosides. Druggability of the parasite enzymes was assessed, as well as the availability of commercial inhibitors for them. Druggable enzymes were then ranked according to their potential for drug repurposing and the 17 most promising enzymes were selected for evolutionary analyses. The constructed phylogenetic trees allowed to assess the degree of conservation among ortholog enzymes from parasitic helminths and their mammalian hosts. Positive selection is absent in all assessed flatworm enzymes. A potential target enzyme for drug repurposing, ribonucleotide reductase (RNR), was selected for further assessment. RNR 3D-modelling showed structural similarities between the E. granulosus and the human orthologs suggesting that inhibitors of the human RNR should be effective against the E. granulosus enzyme. In line with that, E. granulosus protoscolices treated in vitro with the inhibitor hydroxyurea had their viability and DNA synthesis reduced. These results are consistent with nucleotide synthesis inhibition and confirm the potential of a nucleotide salvage inhibitors for repurposing as an anthelmintic.
引用
收藏
页数:12
相关论文
共 50 条
  • [21] Gene expression signature based screening identifies ribonucleotide reductase as a candidate therapeutic target in Ewing sarcoma
    Goss, Kelli L.
    Gordon, David J.
    ONCOTARGET, 2016, 7 (39) : 63003 - 63019
  • [22] Facilitated Drug Repurposing with Artemisinin-Derived PROTACs: Unveiling PCLAF as a Therapeutic Target
    Li, Yan
    Zeng, Zi Wei
    Chen, Di
    Gu, Zhi Cheng
    Yan, Wan Li
    Yue, Ling Yun
    Zhu, Ren Guang
    Zhao, Yong Long
    Chen, Lei
    Zhao, Qing Jie
    He, Bin
    JOURNAL OF MEDICINAL CHEMISTRY, 2023, 66 (16) : 11335 - 11350
  • [23] Mechanism for ribonucleotide reductase inactivation by the anticancer drug gemcitabine
    Pereira, S
    Fernandes, PA
    Ramos, MJ
    JOURNAL OF COMPUTATIONAL CHEMISTRY, 2004, 25 (10) : 1286 - 1294
  • [24] Pharmacokinetic considerations for enhancing drug repurposing opportunities of anthelmintics: Niclosamide as a case study
    Seo, Jeong In
    Jin, Geun-woo
    Yoo, Hye Hyun
    BIOMEDICINE & PHARMACOTHERAPY, 2024, 173
  • [25] Ribonucleotide reductase M2 subunit is a novel diagnostic marker and a potential therapeutic target in bladder cancer
    Morikawa, Teppei
    Maeda, Daichi
    Kume, Haruki
    Homma, Yukio
    Fukayama, Masashi
    HISTOPATHOLOGY, 2010, 57 (06) : 885 - 892
  • [26] Ribonucleotide reductase inhibitors: a new look at an old target for radiosensitization
    Chapman, Tobias R.
    Kinsella, Timothy J.
    FRONTIERS IN ONCOLOGY, 2012, 1
  • [27] Ribonucleotide reductase subunit M2 is a potential prognostic marker and therapeutic target for soft tissue sarcoma
    Das, Basudeb
    Jain, Neha
    Mallick, Bibekanand
    GENE, 2022, 808
  • [28] RIBONUCLEOTIDE REDUCTASE, A COMMON PRIMARY TARGET FOR THE PATHOGENESIS OF IMMUNODEFICIENCY DISEASES
    ULLMAN, B
    MARTIN, DW
    CLINICAL RESEARCH, 1979, 27 (02): : A458 - A458
  • [29] RIBONUCLEOTIDE REDUCTASE - AN INTRACELLULAR TARGET FOR THE MALE ANTIFERTILITY AGENT, GOSSYPOL
    MCCLARTY, GA
    CHAN, AK
    CREASEY, DC
    WRIGHT, JA
    BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 1985, 133 (01) : 300 - 305
  • [30] RIBONUCLEOTIDE REDUCTASE
    SJOBERG, BM
    GRASLUND, A
    ADVANCES IN INORGANIC BIOCHEMISTRY, 1983, 5 : 87 - 110